Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The triglyceride-glucose index serves as a dependable biomarker for gauging insulin resistance linked to cardiovascular disease. Our study was designed to investigate how the trajectory of the triglyceride-glucose index relates to the risk of worsening heart failure and overall mortality in patients aged 60 years and older with chronic heart failure and type 2 diabetes.
Methods: This study enrolled 466 patients who had ≥ 3 medical exams. The formula for calculating the triglyceride-glucose index was ln (fasting triglycerides [mg/dL] × fasting blood glucose [mg/dL]/2). The trajectory of the triglyceride-glucose index in longitudinal analysis was analyzed via linear mixed models. The relationships between the trajectory of the TyG index and the risk of worsening heart failure and overall mortality were analyzed via competing Cox regression analysis and mixed-effects Cox regression analysis.
Results: After the variables adjustment, compared with the first quartile group, the adjusted hazard ratios for worsening heart failure in top quartile group were 2.40 (1.35-3.28) for 10-year follow-up, and 2.09 (1.22-3.58) for overall follow-up duration. The adjusted hazard ratios for overall mortality in top quartile group were 1.99 (1.56-3.14) for 10-year follow-up, and 1.87 (1.22-2.88) for overall follow-up duration. Compared with the low decreasing trajectory, adjusted hazard ratios for worsening heart failure of high decreasing trajectory were 1.37 (1.10-1.71) for the 5-year follow-up, 1.78 (1.10-2.88) for 10-year follow-up, and 1.67 (1.04-2.68) for overall follow-up duration. The adjusted hazard ratios for overall mortality were 2.16 (1.39-3.35) for 10-year follow-up, and 2.23 (1.46-3.40) for overall follow-up duration.
Conclusion: During follow-up, a higher baseline level of TyG index and a high decreasing trajectory were independently associated with long-term worsening heart failure and an increased risk of overall mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929357 | PMC |
| http://dx.doi.org/10.1186/s12933-025-02687-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The CONDUCT-AF trial: Rationale and design of a prospective, randomized, multicentre study comparing conduction system and biventricular pacing in patients undergoing atrioventricular node ablation for heart failure with atrial fibrillation.
Eur J Heart Fail
September 2025
Cardiology Department, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Aims: There is a lack of data from randomized clinical trials comparing treatment outcomes between conduction system pacing (CSP) modalities and biventricular pacing (BVP) in symptomatic patients with refractory atrial fibrillation (AF) scheduled for atrioventricular node ablation (AVNA). The CONDUCT-AF investigates whether CSP is non-inferior to BVP in improving left ventricular ejection fraction (LVEF) and clinical outcomes in heart failure (HF) patients with symptomatic AF undergoing AVNA.
Methods: This study is an investigator-initiated, prospective, randomized, multicentre clinical trial conducted across 10 European centres, enrolling 82 patients with symptomatic AF, HF with reduced LVEF, and narrow QRS.
GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.
JAMA Netw Open
September 2025
Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.
Importance: The cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may vary by body mass index (BMI), but evidence on BMI-specific outcomes remains limited.
Objective: To investigate the associations of GLP-1 RA use with cardiovascular and kidney outcomes across BMI categories in patients with type 2 diabetes.
Design, Setting, And Participants: This retrospective cohort study used the Chang Gung Research Database, a clinical dataset covering multiple hospitals in Taiwan.
Symptoms, coronary artery disease and percutaneous coronary intervention: connecting the dots.
Curr Opin Cardiol
August 2025
National Heart and Lung Institute, Imperial College London.
Purpose Of Review: Symptom relief is now recognized as the primary remit of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease. The relationship between the nature of angina symptoms and the likelihood of successful symptom relief from PCI had not been systematically studied until recently.
Recent Findings: The ORBITA-2 symptom-stratified analysis found that while the severity and nature of symptoms were poorly associated with the severity of coronary disease, the nature of the symptoms powerfully predicted the efficacy of PCI in relieving angina.
Arterial Stiffness in HFpEF: From Clinical Insight to Bedside Action.
Cardiol Rev
September 2025
From the Department of General Medicine, J.S.S. Medical College, JSS Academy of Higher Education and Research, Mysuru, India.
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is increasing in prevalence due to aging populations and comorbidities such as hypertension and diabetes. While echocardiography remains the diagnostic cornerstone, many patients with preserved ejection fraction present with nonspecific symptoms and ambiguous diastolic indices, leading to diagnostic uncertainty and therapeutic delay. Arterial stiffness-quantified by pulse wave velocity, augmentation index, and cardio-ankle vascular index)-is emerging as a key contributor to HFpEF pathophysiology.
View Article and Find Full Text PDFMicroplastics and nanoplastics: tiny threats for cardiovascular diseases?
Cardiovasc Res
September 2025
Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Piazza Miraglia, 2, Naples 80138, Italy.